Few companies have been as eagerly anticipating the new administration of President Joe Biden and Democratic control of Congress as Molina Healthcare Inc.
With two recent acquisitions under its belt, Pasadena-based startup Innova Medical Group Inc. is ramping up procurement and production of rapid antigen tests.
Beverly Hills-based biotech firm Capricor Therapeutics Inc. is about to start work on an entirely new type of Covid-19 test.
The Covid-19 vaccine candidate being developed by two of billionaire Patrick Soon-Shiong’s companies moved a step closer to deployment.
Monrovia-based biopharmaceutical company Xencor Inc. has signed a partnership agreement with UCLA’s Technology Development Group to develop new drugs.
Quantgene's partnership with Vikor Scientific will help commercialize its liquid biopsy genomic test platform.
Local incubator member and digital health company Avhana Health Inc. has been acquired by Wilmington, Del.-based digital medicine products company Amalgam Rx Inc. for an undisclosed sum.
Duarte-based City of Hope has received a $100 million donation from one of its research pioneers, Arthur Riggs.
Venice-based microbial bioscience company Seed Health Inc. has acquired New York-based Auggi Technologies Inc.
UCLA Health has received a $29 million gift from philanthropist Allen Ginsburg and his wife Charlotte to establish a center for precision genetic medicine.
Fulgent Genetics Inc. and Healthvana Inc. are partnering with Los Angeles County to expand at-home Covid testing.
Santa Monica-based direct-to-consumer orthodontics company Byte has been acquired by Charlotte, N.C.-based dental products giant Dentsply Sirona Inc. in an all-cash deal valued at $1.04 billion.
Monrovia-based biopharma company Xencor Pharmaceuticals Inc. has entered into a research collaboration and commercialization agreement with Houston-based University of Texas MD Anderson Cancer Center.
Beverly Hills-based biopharma company Capricor Therapeutics Inc. made two announcements last month involving collaborative agreements.
Culver City-based ImmunityBio Inc. announced Jan. 19 that it has received authorization from South African health officials to begin clinical trials of its Covid-19 vaccine candidate in that country.